论文部分内容阅读
选取2015年1月~2015年12月我院收治的126例老年Ⅱ型糖尿病患者,随机分为治疗组和对照组,每组患者63例,对照组单独使用重组人胰岛素注射液,治疗组患者在对照组的基础上给予患者口服西格列汀;结果:对照组与治疗组在干预前FBG、PBG、HbA_(1c)均不存在显著性变化(P>0.05),干预结束后,对照组与治疗组相比FBG、PBG、HbA_(1c)均存在显著性变化(P<0.05),且治疗组FBG、PBG、HbA_(1c)在干预前后存在显著性差异(P<0.05),对照组FBG、PBG、HbA_(1c)略有降低,但不存在显著性改变(P>0.05);结论:磷酸西格列汀联合胰岛素可以很好地控制患者的血糖,值得在临床上推广。
A total of 126 elderly patients with type 2 diabetes treated in our hospital from January 2015 to December 2015 were randomly divided into treatment group and control group, with 63 patients in each group. In the control group, recombinant human insulin injection alone was used in the treatment group The patients were given sitagliptin orally on the basis of the control group. Results: There were no significant changes in FBG, PBG and HbA_ (1c) between the control group and the treatment group before intervention (P> 0.05). After the intervention, the control group The levels of FBG, PBG and HbA 1c in treatment group were significantly different from those in treatment group (P <0.05), and there were significant differences in FBG, PBG and HbA 1c before and after treatment in control group (P <0.05) FBG, PBG, HbA_ (1c) slightly decreased, but there was no significant change (P> 0.05). Conclusion: Sitagliptin phosphate combined with insulin can control the blood glucose of patients well and is worth to be popularized clinically.